| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | JARID1A; Kdm5a; RBBP2; RBP2;;KDM5A |
| WB Predicted band size | 192 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human KDM5A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于KDM5A抗体的3篇参考文献的简要总结(文献信息为模拟示例，非真实存在)：
1. **文献名称**：*"Development and validation of a specific KDM5A/JARID1A antibody for chromatin immunoprecipitation"*
**作者**：Smith A et al.
**摘要**：该研究开发了一种高特异性的KDM5A兔多克隆抗体，通过CRISPR敲除细胞系验证其特异性，并成功应用于ChIP-seq分析，揭示了KDM5A在乳腺癌细胞中靶向启动子区域调控基因沉默的作用。
2. **文献名称**：*"KDM5A promotes tumor progression through epigenetic silencing of PTEN in colorectal cancer"*
**作者**：Li X et al.
**摘要**：利用KDM5A特异性抗体(货号AB123.抗鼠单克隆)，研究者通过免疫组化和Western blot发现KDM5A在结直肠癌中高表达，并通过去甲基化H3K4me3抑制抑癌基因PTEN，促进肿瘤生长。
3. **文献名称**：*"A pan-cancer analysis of KDM5A expression and its association with chemotherapy resistance"*
**作者**：Wang Y et al.
**摘要**：研究通过商业KDM5A抗体(Cell Signaling, #6787)分析了TCGA数据库及临床样本，发现KDM5A在多种癌症中过表达且与顺铂耐药相关，机制涉及其对DNA修复基因的表观调控。
(注：以上文献为模拟内容，实际引用时需检索PubMed等数据库获取真实文献。)
The KDM5A antibody is a crucial tool in studying the lysine-specific demethylase 5A (KDM5A), also known as JARID1A or RBP2. which belongs to the KDM5 subfamily of histone demethylases. KDM5A specifically catalyzes the removal of methyl groups from tri- and dimethylated histone H3 lysine 4 (H3K4me3/me2), a modification typically associated with active gene transcription. By regulating H3K4 methylation states, KDM5A modulates chromatin structure and gene expression, impacting processes like cell differentiation, proliferation, and DNA repair. Dysregulation of KDM5A has been linked to cancers, where its overexpression often correlates with poor prognosis, drug resistance, and epigenetic silencing of tumor suppressors.
Antibodies targeting KDM5A are widely used in research to detect its expression, localization, and functional interactions. These antibodies enable techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP-seq), aiding in the exploration of its role in epigenetic regulation and disease mechanisms. Validated KDM5A antibodies are essential for distinguishing it from homologous family members (KDM5B/C/D) due to structural similarities within the JmjC domain-containing protein family.
High-quality KDM5A antibodies are rigorously tested for specificity, often using knockout cell lines or siRNA knockdowns. They are critical in both basic research and drug development, particularly in studies targeting KDM5A's oncogenic functions or its potential as a therapeutic biomarker.
×
